Causeway Capital Management LLC Has $6.91 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Causeway Capital Management LLC reduced its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 59.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 522,030 shares of the company's stock after selling 759,162 shares during the period. Causeway Capital Management LLC's holdings in Takeda Pharmaceutical were worth $6,912,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical in the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $40,000. BNP Paribas Financial Markets raised its position in shares of Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares during the period. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.2 %

TAK stock traded up $0.04 during mid-day trading on Friday, hitting $14.69. 1,971,072 shares of the company were exchanged, compared to its average volume of 1,852,919. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.37. The firm's 50 day simple moving average is $14.57 and its 200 day simple moving average is $13.91. The firm has a market cap of $46.73 billion, a P/E ratio of 36.71, a P/E/G ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.